Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$57.52 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.21M
Market Cap
$29.64B
Enterprise Value$35.28B
Total Cash (Recent Filing)$2.93B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)52.9
Beta1.10
Next Earnings
Oct 23, 2025EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding392,155,270
10 Day Avg. Volume4,269,074
30 Day Avg. Volume4,213,967
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue8.20
Enterprise Value/Gross Profit13.96
Enterprise Value/Ebitda33.95
Forecast
1Y Price Target
$100.89Price Target Upside33.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDXCM reported 2Q25 sales of $1.16bn, exceeding consensus expectations by 3%.
Market ExpansionGrowing non-insulin reimbursement and the potential for a CMS coverage update in the next 6-12 months create reliable growth and upcoming catalysts for both sales and profitability.
Product LaunchDXCM's launch of the G7 15-day sensor is expected to be a significant catalyst for growth.
Bears Say
GuidanceThe updated guidance is slightly below investor expectations, seen as conservative.
Stock PerformanceThe stock traded off 10% post earnings despite a solid $33 million beat in the second quarter.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $57.52 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $29.64B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 23, 2025 which is in 37 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 30, 2025. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.444 by $0.036.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.57.
How many shares outstanding does Dexcom have?
Dexcom has 392,155,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.48 in its last earnings report, beating expectations of $0.444. Following the earnings report the stock price went down -9.308%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.89 (33.49% Upside)
$100.89 (33.49% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 139.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.73%
12-Months-Change
Fundamentals
Return on Equity
22.83%
Trailing 12-Months
Asset Growth
7.76%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
DexCom's Q2 2025 earnings call revealed strong revenue growth, significant expansion in coverage, and continued innovation in product offerings, offset by challenges in gross margin and inventory management. Despite concerns about potential CMS competitive bidding, the company's strategic moves and positive clinical evidence position it favorably for future growth.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$100.89
▲(33.49% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
30.13% Mutual Funds
25.71% Other Institutional Investors
14.44% Public Companies and Individual Investors